[1] Ohnuma K, Hatano R, Komiya E, et al. A novel role for CD26/dipeptidyl peptidase IV as a therapeutic target[J]. Front Biosci (Landmark Ed), 2018, 23:1754-1779. [2] Farag S S, Srivastava S, Messina-Graham S, et al. In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies[J]. Stem Cells Dev, 2013, 22(7):1007-1015. [3] 李颖. 间充质干细胞条件培养基对糖尿病肾病大鼠肾脏的保护作用[J]. 中华老年多器官疾病杂志, 2017, 2(16):140-143. [4] Wang M T, Lin S C, Tang P L, et al. The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction[J]. Cardiovasc Diabetol, 2017, 16(1):89. [5] Cordero O J, Varela-Calvino R, Lopez-Gonzalez T, et al. Anti-CD26 autoantibodies are involved in rheumatoid arthritis and show potential clinical interest[J]. Clin Biochem, 2017, 50(16-17):903-910. [6] Fernandez-Paredes L, Casrouge A, Decalf J, et al. Multimarker risk stratification approach at multiple sclerosis onset[J]. Clin Immunol, 2017, 181:43-50. [7] Papazafiropoulou A K, Papanas N, Trikkalinou A, et al. The oral dipeptidyl-peptidase-4 inhibitor sitagliptin Increases circulating levels of stromal-derived factor-1 alpha[J]. Exp Clin Endocrinol Diabetes, 2018, 126(6):367-370. [8] Farag S S, Nelson R, Cairo M S, et al. High-dose sitagliptin for systemic inhibition of dipeptidylpeptidase-4 to enhance engraftment of single cord umbilical cord blood transplantation[J]. Oncotarget, 2017, 8(66):110350-110357. [9] Waget A, Cabou C, Masseboeuf M, et al. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice[J]. Endocrinology, 2011, 152(8):3018-3029. [10] 刘珊珊. LC-MS/MS法分析人血浆中西格列汀浓度及其应用研究[J]. 天津医药, 2018, 10(46):1096-1101. [11] Balakrishnan A, Gloude N, Sasik R, et al. Proinflammatory dual receptor T cells in chronic graft-versus-host disease[J]. Biol Blood Marrow Transplant, 2017, 23(11):1852-1860. [12] 范一帆,齐丹,刘佳馨,等.鞘磷脂合酶抑制剂对血管紧张素Ⅱ诱导的高血压小鼠心肌纤维化的影响[J].首都医科大学学报,2016,37(6):731-735. |